Literature DB >> 1356418

Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice.

M T Kuo1, J Y Zhao, L D Teeter, M Ikeguchi, F V Chisari.   

Abstract

The expression of multidrug resistance (mdr) genes was investigated in the livers of transgenic mice that express the human hepatitis B virus large envelope polypeptide under the transcriptional control of a liver-specific promoter. These mice develop a storage disease due to the accumulation of a nonsecretable form of hepatitis B surface antigen in the hepatocyte. Liver cell injury is followed by a hepatocellular proliferative response, dysplasia, microscopic nodular hyperplasia, and finally hepatocellular carcinoma. The expression of mdr1, mdr2, and mdr3 genes was analyzed in livers at different stages of the disease by RNase protection assay, Western blot, and immunohistochemistry. RNase protection assay revealed that mdr3 mRNA expression was moderately increased in tissue with microscopic nodular hyperplasia and significantly overexpressed in hepatocellular carcinoma but undetectable in earlier stages of the disease. Western blot using isoform-specific anti-mdr3 antibody demonstrated that the expression of mdr3 protein reflected the steady-state level of mdr3 mRNA. Immunohistochemical analyses using anti-mdr3 isoform-specific antibody and monoclonal antibody C219, which recognizes all the three mdr isoforms, demonstrated selective overexpression in preneoplastic foci during the stage of microscopic nodular hyperplasia as well as in neoplastic hepatocytes in hepatocellular carcinoma. No consistent activation of mdr1 and mdr2 (but occasional coactivation with mdr1) genes during hepatocarcinogenesis was observed. Our results suggest that the hepatocellular mdr3-specific activation mechanism is associated with the late events of hepatocarcinogenesis in this model. The predictable kinetics of mdr gene expression in this transgenic tumor model suggest that it is suitable for future studies of the mechanism of mdr gene activation and the possible pharmacological consequences for mdr3 gene expression of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356418

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  7 in total

1.  The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium.

Authors:  Halla S Nimeiri; Deepti A Singh; Kristen Kasza; David A Taber; Rafat H Ansari; Everett E Vokes; Hedy L Kindler
Journal:  Invest New Drugs       Date:  2009-08-11       Impact factor: 3.850

2.  Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.

Authors:  El Mehdi Tazi; Ismail Essadi; Hind M'rabti; Anass Touyar; Pr Hassan Errihani
Journal:  N Am J Med Sci       Date:  2011-04

Review 3.  Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.

Authors:  D Germano; V Tinessa; E Barletta; L Cannella; B Daniele
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

Review 4.  P-glycoprotein, multidrug resistance and tumor progression.

Authors:  G Bradley; V Ling
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

5.  A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).

Authors:  Jennifer J Knox; Sharlene Gill; Timothy W Synold; James J Biagi; Pierre Major; Ron Feld; Christine Cripps; Nancy Wainman; Elizabeth Eisenhauer; Lesley Seymour
Journal:  Invest New Drugs       Date:  2008-01-15       Impact factor: 3.850

6.  Activation of the mouse mdr3 gene by insertion of retroviruses in multidrug-resistant P388 tumor cells.

Authors:  P Lepage; A Devault; P Gros
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

7.  mRNA levels of related Abcb genes change opposite to each other upon histone deacetylase inhibition in drug-resistant rat hepatoma cells.

Authors:  Adám Sike; Enikő Nagy; Balázs Vedelek; Dávid Pusztai; Péter Szerémy; Anikó Venetianer; Imre M Boros
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.